Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Use of AP-1 activators to treat glaucoma and ocular hypertension

Use of AP-1 activators to treat glaucoma and ocular hypertension

US Patent 7005446 · Granted Feb 28, 2006

Estimated economic value: $69,465,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Devices, systems, and methods for modeling ocular translaminar pressure gradient2023
Transferrin/transferrin receptor-mediated siRNA delivery2018
Methods of treating ophthalmic diseases using NPR-B agonists2017
RNAi-mediated inhibition of connexin 43 for treatment of IOP-related conditions2017
Transferrin/transferrin receptor-mediated siRNA delivery2017
RNAI-mediated inhibition of frizzled related protein-1 for treatment of glaucoma2017
RNAi-mediated inhibition of connexin 43 for treatment of IOP-related conditions2016
RNAi-related inhibition of TNF-alpha signaling pathway for treatment of ocular a2016
Methods of treating ophthalmic diseases using NPR-B agonists2015
RNAi-mediated inhibition of connexin 43 for treatment of IOP-related conditions2015
RNAi-related inhibition of TNF alpha signaling pathway for treatment of ocular a2015
Transferrin/transferrin receptor-mediated siRNA delivery2015